NT201-E Major Traumatic Wounds (Equine)

Horses are innately highly active animals hence are prone to physical injuries caused by fencing, gates, farm and building structures and various elements in their natural environment. In high value performance horses, traumatic wounds can quickly end promising, competitive careers. These wounds are at high risk for infection, inflammation, excessive granulation tissue growth (proud flesh), slow epithelialization and other problems. These challenges make treatment of traumatic wounds long, difficult and extremely expensive.

NT201-E is a recombinant horse NELL1 protein delivered via FDA-approved equine collagen bioscaffold and directly implanted into injured tissue within a few days of injury. Large animal trials are underway to demonstrate efficacy and dosing for increasing the rate and quality of wound healing in horses.

NT201-H Major Trauma (Human)

According to NHDS there are about 80,000 major trauma patients hospitalized each year in the U.S. the majority of whom will suffer damage to, or loss of, skeletal muscle. Current approaches (e.g. scaffolds and matrices with or without cells and/or bioactive factors) have not demonstrated the ability to regenerate functional muscle in a large wound. For most patients, building new muscle is a slow process brought on by physical therapy, which is often inefficient because of limited mobility and persistent pain. NellOne studies suggest the potential to accelerate the regeneration of skeletal muscle after major trauma and provide restoration of function.

NT 301: Cardiac Muscle Regeneration

There are more than 800,000 heart attack cases each year in the US alone. Many companies are pursuing cell implantation approaches, which face challenges such optimal cell type choice, poor cell engraftment at the treatment site, adverse immunologic responses and cell storage difficulties. Others are developing growth factor type therapies, which may lead to the accumulation of new cell mass, but fail to orchestrate cellular organization into functional contractile tissue. NellOne research suggests that NELL1 maintains an active re-growth and remodeling environment via the ECM enabling true regeneration of cardiac muscle tissue after heart attack.

These investigational drug products have not been approved by the US Food and Drug Administration.